Qualifications REGISTRATION


EMAIL CONTACT DETAILS


CURRENT AFFILIATION
 MBBS; MD; DCH; DM (NEPHROLOGY); MRCPCH (UK); FRACP
Unconditional Unrestricted General and Specialist Registration – AHPRA AUSTRALIA (AHPRA: MED 0001549510)
Hemant.kulkarni@health.wa.go.au 
admin@drkulkarni.com.au   
Fax: +61 8 6210 1194
East Metro Health Services (RPH and Armadale Health Services) Wexford Nephrology: SJOG –HC, Murdoch Lead, Renal Health Network – Division of Clinical Excellence, DoH -WA
Skills & Abilities Clinical Role as Renal Physician with interest in Adult and Paeditric Nephrology including Dialysis and Transplantation; Transitional Care in Nephrology
Leadership and Policy Development
Teaching and Education  Research: Clinical Research, and Evidence Based clinical Care
CURRENT POSITIONS Co –Clinical Lead, Renal Health Network, Health Networks Branch, Dept of Health, WA 2012 – till date
Head of Dept – Armadale Renal Services – Armadale Health Services WA June 2004 – till date
Renal Physician – Royal Perth Hospital and Health Services (Post reconfiguration of Health Services): Feb 2015 – till date
Renal Physician – Fremantle Hospital and Health Services June 2004 – Jan 2015 (Until reconfiguration of Health Services)
Renal Physician – St John of God Health Care (Murdoch); Peel Health Campus (Mandurah) & Mount Hospital – June 2004 – till date
GRANTS and AWARDS Associate Investigator for NHMRC Grant ($ 1 million) for Feb 2014: APP1079502 Chronic Kidney Disease Centre of Research Excellence https://cre-ckd.centre.uq.edu.au/profile/95/hemant-kulkarni

June 2013: Kidney Health Australia: OPERATION ANGEL Award: For Inspirational Contribution to the patients with Kidney Care in Western Australia

2012- 2013: ANZSN-Amgen Quality Assurance Grant ($ 10,000) for assessment of the development of Vascular access centre in Outer Metropolitan Hospital

2007: ANZSN- NEPHROLOGY RESEARCH GRANT ($ 35,000) for clinical research in Iron Overload in Haemodialysis population1997:  First Rank in University of Mumbai for DM (Nephrology) examinations

Dec 1994: Pfizer Postgraduate Medical Award & Medallion & Scroll of honour for securing highest marks in Medicine in MBBS

1990-1991: N F Surveyor Gold Medal for 1ts Rank in MBBS at Grant Medical College, University of Mumbai

March 1991: Prof M B Gharpure Memorial Prize (1st in Pharmacology) at Grant Medical College, University of Mumbai

Merit awards and Scholarships by Govt of India and Maharashtra: HSC certification
EDUCATION 2003: FRACP: Royal Australasian College of Physicians
2002: AMC: Australasian Medical Council Examinations
1999: MRCPCH (UK): Royal College of Physicians, United Kingdom
1997: DM (NEPHROLOGY): Doctor of Medicine, University of Mumbai, India
1995: MD (PEDIATRICS): Doctor of Medicine, University of Mumbai, India
1994: DCH: College of Physicians and Surgeons, Mumbai, India
1992: MBBS : Grant Medical College, University of Mumbai, India
ACADEMIC APPOINTMENTS     PRIOR WORK EXPERIENCE 2003 – 2004: Hon. Assistant Lecturer, Department of Paediatrics, Monash UNIVERSITY. MELBOURNE VIC.    

DEC 1998 – DEC 1999: Clinical Lecturer in Paediatric Nephro-Urology; Guy’s and St. Thomas’s Hospital, and Kings College (University of London)  —————————————————————————————————-
Dec 2013 – Jan 2014:
SABBATICAL: Transplant Fellowship: Royal Prince Alfred Hospital, SYDNEY (inclusive of Westmead Hospital for Children and Westmead Adult Hospital)  
Feb 2003 – June 2004:
Senior Registrar Nephrology (Feb- April 2004);
Clinical Fellow – Paediatric Nephrology (Feb 03- Feb 04),
Monash Medical Centre, Melbourne VIC & Latrobe Regional Hospital, Traralgon. Hon. Assistant Lecturer, Department of Paediatrics, Monash UNIVERSITY; AND Visiting Paediatrician, Latrobe Regional Hospital, Traralgon.    
Jan 2002 – Jan 2003:
Paediatrics & Specialties at Ballarat Base Hospital, VIC AND Princess Margaret Hospital for Children, Perth. WA  
Jan 2000 – Jan 2002: Senior Registrar in Nephrology, Dialysis and Transplantation, Royal Perth Hospital, Perth. WA  
Dec 1998 –  Nov 1999: Hon. Specialist Registrar and Clinical Lecturer in Paediatric Nephro-Urology; Guy’s and St. Thomas’s Hospital, and Kings College (University of London)  
Jan 1998 – Dec 1998: Sr Reg Paediatric Nephrology, Women’s & Children’s Hospital, Adelaide, South Australia.  
June 1995 – Dec 1997: Training for DM (Nephrology); University of Mumbai, India.  
1992 – 1995:  Training in Paediatrics & Specialities; University of Mumbai, India.  
1986 – 1992: MBBS: Grant Medical College, University of Mumbai.
Memberships Royal Australasian College of Physicians
Australian and New Zealand Society of Nephrology
Australian and New Zealand Society of Paediatric Nephrology
Australian Medical Association
Indian Society of Nephrology and
Indian Society of Organ Transplantation (Life Member)
Medical Advisory Role Linear Research Institute: 2019 – 2020
Vifor Pharmaceuticals – Product Iron carboxymaltose (2013-2014)
Novartis Pharmaceuticals – Product Afinitor for Tuberous Sclerosis (2014) 
  TEACHING AND LEARNING:
UG TEACHING ROLE Clinical Sr Lecturer, Medical School – Curtin University (2019 till date)
POST GRADUATE TEACHING in NURSING AND MEDICINE   Train and establish the FIRST Renal Nurse Practitioner in the Western Australia at Armadale in 2006.
Renal NP was runner up for Nurse of the Year Award (DoH – WA) in 2016 with the clinical research.  

Involvement in supervision of trainees in various stages of career.

Senior Examiner for Royal Australasian College of Physicians examinations since 2012

Reviewer for National and International Medical Peer reviewed Journals

Royal Australasian College of Physicians – Nephrology Division: Reviewer of Advanced Training Project Assessments and involvement with structured learning projects

 
 EXAMINER FOR FELLOWSHIP EXAMINATION FOR ROYAL AUSTRALASIAN COLLGE OF PHYSICIANS: 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019
: Associate Investigator in: NHMRC Application for Feb 2014: APP1079502 Chronic Kidney Disease Centre of Research Excellence Australia’s first CRE in chronic kidney disease (CKD) will be established through an established registry and surveillance collaboration. This will develop profiles of CKD patients in various primary care and renal practice settings, in several states, and in Indigenous and non-indigenous people; and follow the courses of those patients, and their outpatient trajectories, management, hospitalisations, outcomes, and costs.
Recent COURSES COMPLETED Leader Ship Course: Sept – Nov 2019 -: Health Networks Branch: Div of Clinical Excellence, DoH – WA
Leadership Course (8.5 days): By Institute of Leadership; Dept. of Health (2014)
GCP for Research
Teaching on the Run: Facilitators Course (July 2012)
Organisation of courses/ study day National Clinician Network Forum: Renal Division: Facilitator of the forum workshop (April 2014) Ultrasound Course: A satellite course to ANZSN Annual Meeting. Australian and New Zealand Society of Interventional Nephrology. Sept 2010  Bone Mineral Study Day: Renal Nurse Practitioners – Western Australia: 19th June 2010
   
  PROJECTS as a CLINICAL LEAD OF HEALTH NETWORKS BRANCH
CPAC GUIDELINES  JULY 2012 Developed / updated CPAC Guidelines for Nephrology (July 2012) http://www.gp.health.wa.gov.au/cpac/speciality/docs/CPAC%20Renal%20Summary%20101125.pdf http://www.gp.health.wa.gov.au/CPAC/speciality/guidelines/Nephrology%20CPAC%20Summary%202013.pdf Clinical Priority Access Criteria (CPAC) refers to an outpatient categorisation system that allows the prioritising of clinical conditions. CPAC assist GPs to assess relative patient need and in doing so, ensure that patients who require treatment more urgently are seen first by the Outpatient Clinic. CPAC guidelines are used to select and prioritise patients for outpatient services in Western Australian hospitals. The objective of CPAC is to provide more comprehensive information with each new GP referral to hospital specialists and therefore achieve the following: Reduce inappropriate referrals; commence specialist assessment and treatment more quickly; involve the GP in the patient’s hospital care; Reduce duplication of investigations and Reduce waiting time for outpatient based on clinical priority.
National surveillance network for chronic Kidney disease (CKD) 2014 We are involved in a collaboration of programs that are already collecting CKD data in Australia in order to develop regional profiles of CKD and its outcomes in various settings within Australia. Several partners have collaborated in grant applications to NHMRC and BUPA. The transformed meta-data will underpin regional maps of CKD and support informed predictions and interventions, well before information flows from more harmonised electronic approaches. Partners in this project are: W Hoy, HG Healy, D Waugh, M Jose, I Katz, S Pirabhahar, R Walker, C Nelson, K Panaretto, A Salisbury and T Mathew. Towards a national surveillance network for chronic Kidney disease (CKD).
 (2013-2014) CLINICAL STANDARDS PATHWAY – SMHS & Renal health network collaboration (RENAL) Lead facilitator for State-wide Policies (collaboration with NMHS and WACHS): http://www.healthnetworks.health.wa.gov.au/network/renal.cfm Hepatitis B Vaccination in Advanced CKDParathyroidectomy in Advanced CKDParenteral IV Iron therapy on HD and advanced CKD (In draft)Dialysis Access (PD and HD) (In draft) Contributor in other CPS: Removal Non-tunnelled Haemodialysis CatheterCentral Venous Catheter: Anticoagulation LockSite Representation for implementation at Armadale Health ServicesSpecimen Collection and Pathology Results
KPI project: initiative of renal health network AND national forum (2014) The Renal Health Network (RHN) and its Executive Advisory Group (EAG) led by Co-Clinical Leads have developed a set of Quality Improvement (QI) Indicators for Renal Replacement Therapy (RRT) for state-wide use. Health Networks are working with CMO office as a Data Custodian, with individual units contributing data at intervals. This initiative is being collaborated with Renal Networks of other states to develop the Nationally agreed set of QUALITY IMPROVEMENT INDICATORS.
GP upskilling initiative (2014) in collaboration with primary care networks Advanced Renal Care in General Practice Service (ARC GPS) is supported by Renal and Primary Care Networks of Health Networks Branch to support GP up skilling in Renal Medicine. This aims to deliver improved clinical outcomes for renal patients in community, reduce hospital out-patient attendances and emergency admissions over time.  This Pilot project is planned as a 5 day rotation of Primary Care Physicians with clinical attachment to the Renal Unit – Sir Charles Gairdner Hospital with direct supervised exposure to CKD Clinics, Haemodialysis, Peritoneal Dialysis, Transplantation, Vascular access and inpatient care; and involvement in educational sessions. The experience of this project over 12 months will be used for further expansion to SMHS after restructuring and reconfiguration.
Transitional care framework  (health networks initiative)  I have special interest in the TRANSITIONAL CARE as a qualified Paediatric and Adult Nephrologist. 2009: Transitional care – Model of Care: I was member of the working party and involved in the completion of Model of Care. The Transition Framework is developed by the Child and Youth Health Network WA. This Framework provides new focus on improving the transition of young people with chronic disease and disability from paediatric to adult care. 2014: Panel Member (NCN Forum) and Representative of Renal Health Network for National Clinicians Network Forum in April 2014.
 
development of policies/ protocols (Other than cps- smhs documents summarised above) Armadale Hospital and Health Services: Member of the MEDICAL SUBSPECIALITY COMMITTEE: Actively developed and participated in formation, modification, writing new policies for the hospital as well as Renal Unit. Multiple policies and protocols are developed since 2004 with patient centric care (On Intranet) and include:
Nurse Practitioner related Protocols / projects: http://www.nursing.health.wa.gov.au/docs/career/np/smahs/akdh_warfarin_therapy.pdf http://www.nursing.health.wa.gov.au/docs/career/np/smahs/akdh_man_renal_anaemia.pdf http://rsa2013.org/cms/wp-content/uploads/2012/06/Sat-GrandBallroom12-1140-Light.pdf Bone Mineral Disease management;
Hepatitis B Vaccination Protocol; Anticoagulation Protocol, and othersProphylaxis and Anticoagulation prior to Dental Procedures in Dialysis population
Fremantle Hospital Protocols (SELECTED RECENT Policies): Peritoneal Dialysis Related Peritonitis (Initial Treatment) AlgorithmPeritoneal Dialysis Related Peritonitis (Subsequent Management) AlgorithmParathyroidectomy in CKD (2009)Multiple departmental policies and protocolsIV Iron infusions (Iron Polymaltose, Iron Dextran and Iron Carboxymaltose): 2013
Renal palliative care pathway: model of care (July-2012)   This Model of Care describes a care pathway for the establishment of an integrated patient-centric multi-disciplinary renal palliative care service. The service has a strong linkage with the palliative care team and primary care practitioners, with active involvement of the patient and carers in decision making. The service encompasses patient and family education, symptom management protocols, advance care planning, Liverpool Care Pathway for the last days and hours of life, and bereavement support. This document is ratified by State Health Executive Forum in July 2012; with strong support for the initiative.
Renal palliative care pathway implementation plan (2012-2014) Implementation of the proposed pathway is continuing at 2 sites: 1 tertiary centre (Fremantle Hospital) and 1 Satellite Unit (Armadale Hospital) within existing resources. Ethics application to WA Aboriginal Ethics Committee and WA Health Ethics is continuing. A rural centre (Kalgoorlie) is also planned. These are continued within existing resources under my leadership.
Vascular access pathway: health networks initiative This project document explores the status of Vascular Access services within WA and makes recommendations to improve rates of native Vascular Access and avoidance of temporary lines. Key Performance Targets are suggested to access services, including the recommendation for need of development of Vein Preservation Policy.  This document is awaiting SHEF tabling since Oct 2012. 
Safety and Quality: Involvement in various HOSPITAL & STATE committees Medical Subspecialty Committee at Armadale Health Services Drugs and Therapeutics Committee, Armadale Health Services Mortality and Morbidity Meetings: Fremantle Hospital Renal Unit WA Kidney Transplant Services: Meetings (Council and Members) Root Cause Analysis involvement at SMHS wide Renal Dialysis Reference Group Clinical Review Committee: WA Home Dialysis Programme Renal Management Meetings (Armadale and Fremantle Hospital) Interdepartmental meetings: Histopathology; Journal Clubs, Grand Rounds and others

 
   
  PUBLICATIONS: NATIONAL AND INTERNATIONAL
  
publications:RESEARCH GATE: https://www.researchgate.net/profile/Hemant_Kulkarni2/publications Public URL for Google Scholar http://scholar.google.com.au/citations?user=gRzjH2wAAAAJ Light C; Kulkarni H (Mar 2018). Booster hepatitis B vaccination in haemodialysis patients: Five-year prospective observational study Renal Society of Australasia Journal  Volume 14 Issue 1: 9-13 (Mar 2018)
Holman, R, Olynyk, JK, Kulkarni, H, and Ferrari, P (2017), Characterisation of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. Nephrology, Feb 2017, doi: 10.1111/nep.12735.
SD Roger, CA Gaillard, AH Bock, F Carrera…H Kulkarni (As Investigator Group)… et al.  Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.  Nephrology Dialysis Transplantation, 2016 doi: 10.1093/ndt/gfw264
Hoy, W. E., H. G. Healy, D. Waugh, M. D. Jose, H. Kulkarni, I. Katz, C. Nelson, K. Panaretto, and R. Walker. “Towards a national surveillance network for chronic kidney disease (CKD).” In Nephrology, vol. 19, pp. 58-88. 2014.
AL Graves, M Texler, L Manning, H Kulkarni. Successful treatment of renal allograft and bladder malakoplakia with minimisation of immunosuppression and prolonged antibiotic therapy. Nephrology, Vol 19, Suppl 1, 18-21, April 2014.
H Kulkarni, N Lenzo, A McLean‐Tooke. Causality of rhabdomyolysis and combined tetanus, diphtheria and acellular pertussis (Tdap) vaccine administration. The Journal of Clinical Pharmacology 53 (10), 1099-1102, 2013
DW Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al…The Effects of Biocompatible Compared with Standard Peritoneal Dialysis Solutions on Peritonitis Microbiology, Treatment, and Outcomes: the balANZ Trial. Peritoneal Dialysis International 32 (5), 497-506 ; 2012DW
Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al…Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes: J Am Soc Nephrol 23, 1097-1107 , 2012
DW Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al…The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial Nephrology Dialysis Transplantation. 2012
Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St. Pierre T, and Olynyk J. Serum Iron Markers Are Inadequate for Guiding Iron Repletion in Chronic Kidney Disease Clin J Am Soc Nephrol Jan 2011 (Published online on September 28, 2010 as doi:10.2215/CJN.04190510)
Clark BM, Boan P, Kulkarni H. A Case of Legionella longbeachae Pneumonia Complicated by Rhabdomyolysis and Acute Renal Failure Requiring Hemodialysis. Infectious Diseases in Clinical Practice. 18(6):413-416, November 2010.
JK Olynyk, P Ferrari, H Kulkarni, TC Tan, D Trinder. Non-invasive characterisation of significant hepatic iron overload in hyperferritinemic subjectsHEPATOLOGY, Vol 48, Issue 4, 1170A, 2008
Singer R, Rhodes H, Chin G, Kulkarni H, Ferrari P. High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. Nephrology (Carlton), 2008: Volume 13 Issue 1 Page 17-22.Howman H, Kulkarni H. Antibody-mediated acquired Pure Red Cell Aplasia after treatment with darbepoetin – Nephrology Dialysis Transplantation 2007 22(5):1462-1464.
Thomas MA, Luxton G, Moody HR, Woodroffe AJ, Kulkarni H, Lim W, Christiansen FT, Opelz G. Subjective and quantitative assessment of patient fitness for cadaveric kidney transplantation: the “equity penalty”.  Transplantation. 2003 Apr 15;75(7):1026-9.
H Kulkarni, K Jureidini, P Trnka, P Henning, R Vigneswaran, S Harris  Cystatin C is a promising marker of renal function in newborns during first 3 months.  Nephrology Dialysis Transplantation 18 (18 (suppl 4): 808-813.), 808-813  2003Playford D, Kulkarni H, Thomas M, Vivian J, Low A, Mander J, Perlman D, Finch P. Intra-ureteric capsaicin in loin pain haematuria syndrome: efficacy and complications. British Journal of Urology Int. 2002 Oct;90(6):518-21.
Kulkarni H, Goldwater PN, Martin A, Bettelheim KA. Escherichia coli ‘O’ group serological responses and clinical correlations in epidemic HUS patients. Comp Immunol Microbiol Infect Dis. 2002 Jul;25(4):249-68.
H Kulkarni, S Bichu, U Oza, A Kirpalani. Sulphonamide crystalluria induced acute renal failure in a renal allograft. —A case report, Indian Journal of Nephrology, Vol 7, No 1, 20-21, Jan-Mar 1997.
Patnekar PN, Kulkarni HA, Khopkar SR, Kulkarni VS, Nerurkar RS. Nevus flammeus in tuberous sclerosis Indian Pediatr. 1995 Sep;32(9):1038-9.
H KULKARNI: Antiphospholipid Syndrome in a single kidney- A case report: Indian Journal of Renal Sciences, 1999.
H KULKARNI: Can Cystatin C replace creatinine as a marker of renal function? Review article in Indian Journal of Renal Sciences, 1999.
  REVIEWER:  Journal Manuscripts and RACP – Nephrology advanced trainee projects
(UPDATED MAY 2019)   bcr-2019-230363: Collapsing glomerulopathy related to BK virus in a patient with acute T cell leukemia/lymphoma syndrome. Liu, Baoqiong; Meng, Lingbin; Guan, Xuan; Manoucheri, Manoucher – BMJ- Case Reports – May 2019bcr-2018-229148 Episodic hematuria in a young boy – do not miss familial idiopathic hypercalciuria. Bhattacharya, Deepanjan; Tiewsoh, Karalanglin; Rathore, Vinay; Dawman, Lesa. BMJ-Case Reports Feb 2019bcr-2018-228554 Chronic tinea corporis and delayed kidney transplantation wait-listing: patient-defined health service transformation. Hughes , Jaquelyne ; Kirkham, Renae; Aye Min, Okka; Majoni, Sandawana. BMJ-Case Reports: Jan 2019bcr-2018-224754.R1 Genitourinary malakoplakia after kidney transplantation. Khojah, Suhail; Haig, Aaron; Chan, Nancy; Hosseini-Moghaddam, Seyed M.  BMJ-Case Reports: Jun 2018A new Cardio- renal axis: Peritoneal dialysis catheter placement in the cardiac catheter suite. A Research Project. RACP-Advanced Training Project: Feb 2018Spontaneous atraumatic splenic rupture following intravenous immunoglobulin for parvovirus B19  associated pure red cell aplasia in a renal transplant patient. RACP-Advanced Training Project: Dec 2017eMAP:CKD electronic diagnosis and management assistance to primary care in chronic kidney disease. RACP-Advanced Training Project: Nov 2017What’s new in Paediatric Hypertension? (A Narrative Review article). A Review. RACP-Advanced Training Project: Nov 2017The incidence of cytomegalovirus (CMV) viraemia after renal transplantation with the increasing use of Anti-thymocyte globulin (ATG) in high immunological risk patients. Clinical Research Project. RACP-Advanced Training Project: Oct 2017Patterns of medication prescribing for mineral bone disease and adherence to guidelines; single centre audit of haemodialysis patients. RACP-Advanced Training Project: Oct  2017Overall and site-specific cancer mortality in patients on renal replacement therapy. Research Project. RACP-Advanced Training Project: Oct  2017Patient and physician global assessment of overall health in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. A Research Project. RACP-Advanced Training Project: Oct  2017Graft Outcomes by Kidney Donor Risk Index (KDRI) score in Paediatric Renal Transplant Recipients in Australia and New Zealand. Abstract review. RACP-Advanced Training Project: Sept 2017Prevalence of sarcopenia in patients on dialysis and the factors associated with sarcopenia in this population. Research Project. RACP-Advanced Training Project: Sept 2017Epstein- Barr virus encephalitis in a sero-mismatch renal transplant recipient. Case report. RACP-Advanced Training Project: Sept 2017CATEGORY 1: Audit/QA epidemiology of AKI at a tertiary care centre in Sydney. Impact of delay to consult specialised renal services on LOS and costs. Project. RACP-Advanced Training Project: Sept 2017Effect of bariatric procedures on renal and non-renal parameters in obese CKD patients. Clinical Research Report. RACP-Advanced Training Project: Jun 2017Chyluria: When is proteinuria “not proteinuria”? In -depth review and case report. Journal of Paediatrics and Child Health – Feb 2017. Early prediction and avoidance of delayed graft function in a rodent of renal transplantation models: Use of biomarkers to monitor injury and recovery. RACP-Advanced Training Project: Jan 2017Pulmonary Embolism Associated with Endovascular Thrombolysis for Arteriovenous Fistula Thrombosis. RACP-Advanced Training Project: – Dec 2016Patients Commencing Peritoneal Dialysis following a failed renal transplant have accelerated decline in residual renal function compared ti de-novo PD patients. RACP-Advanced Training Project:  – Nov 2016Psychosocial evolution of living organ donors: an international professional survey. RACP-Advanced Training Project:  – Oct 2016High Incidence of arterial and venous thrombosis in ANCA-associated vasculitis (AAV) – RACP-Advanced Training Project:  – Oct 2016 Renal units with Vascular Access Nurses in Australia and New Zealand do not have higher rates of patients starting haemodialysis and arteriovenous fistula or graft. – RACP-Advanced Training Project:  – Oct 2016 Late Antibody Mediated Rejection in Renal Transplant: Retrospective review of outcomes and prognostic indicators –RACP-Advanced Training Project:  – Sept 2016Epidemiology of biopsy-proven glomerulonephritis in Queensland adults. RACP-Advanced Training Project – Jun 2016.A four-year single centre experience of BK nephropathy managed with a Cidofovir-based regimen. RACP-Advanced Training Project:  – Jan 2016Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis. RACP-Advanced Training Project:  – Oct 2015Solitary Crossed Renal Ectopia: Concurrence of Posterior Urethral Valve and Hypospadias,”  Amin Bagheri, Reza Khorramirouz, Sorena Keihani, Mehdi Fareghi and Abdol Mohammad Kajbafzadeh. Hindawi Publications: May 2015Maintenance of Blood Ionized Calcium does not Prevent Negative Calcium Flux in Regional Citrate Haemodialysis. Blood Purification. 29th July 2013Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation. Jour of Clinical and Developmental Immunology. March 2013Safety of a rapid infusion protocol of iron polymaltose. Fremantle Hospital and Health Services: FHHS Drug Bulletin, Volume 37 Number 3, 2013: Angiotensin converting enzyme inhibitors and aortic arch obstructive malformations’ Indian Journal of Medical Sciences. Sept 2006A case of Marfan’s Syndrome with Aminoaciduria. Indian Journal of Medical Sciences. Jan 2006  
  RESEARCH:
INVESTIGATOR in MULTICENTRE STUDIES Reducing the burden of dialysis Catheter Complications: a National approach (REDUCCTION Partnership project) : 2016- till date PRINCIPAL INVESTIGATOR for Western AustraliaStudy conducted in Australia, New Zealand and other Countries wide, and Co-ordinated via The George Institute for Global Health AUSTRALIAPublications: Smyth, B., Kotwal, S., Gallagher, M., Gray, N. A., & Polkinghorne, K. (2018). Dialysis catheter management practices in Australia and New Zealand. Nephrology (Carlton). 2018 Sep 28. . Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30267459. doi:10.1111/nep.13507
  205270: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat in Non-Dialysis participants evaluating Hemoglobin and Quality of life (ASCEND-NHQ)PRINCIPLE INVESTIGATOR – Trials WestExpected recruitment start date: June – July 2019
  NMHRC Chronic Kidney Disease Centre of Research Excellence (2015-19): Australia’s only CRE in CKD, dedicated to improving CKD knowledge and management across the health care spectrum, by survellince, practice improvement, biomarker research program and health economicsASSOCIATE INVESTIGATOR: CKD-CRE; CKD-QLDPublications: Venuthurupalli SK, Healy HG, RG Fassett, Cameron A, Wang Z, and Hoy WE; on behalf of the NHMRC CKD.CRE and the CKD.QLD Collaborative. Chronic Kidney Disease, Queensland: Profile of patients with chronic kidney disease from regional Queensland, Australia: A registry report. Nephrology (Carlton) 2019 https://doi.org/10.1111/nep.13567
   
investigator initiated trails/ audits Impact of Nurse Practitioner led management of Renal Anaemia in CKD population Screening for renal disease in asymptomatic normal population on World Kidney Day Incidence of Vitamin D deficiency in Haemodialysis population AND Effect of intervention with Vit D in deficient haemodialysis populationFinancial impact on reduction in Hb target in a Satellite Dialysis Unit Cystatin C in Preterm infants as a marker of renal function Intradermal Hepatitis B vaccination in Dialysis / CKD population 
THESIS submission for MD (1995 and 1997) – Low Molecular weight heparins in HD (1995-97): Thesis submitted to University of Mumbai. 1997 – Neonatal Skin lesions: Prospective Study (1992 – 1995): Thesis submission to University of Mumbai. 1995
research  PI: Prospective observational study of correction of Vit D deficiency by cholecalciferol (2009- till date) – Armadale Dialysis UnitPI: Study of progression and prevalence of CKD in population in WA (2003-2013) – Planned with RDRG, Epidemiology Branch and Data linkage of DoHPI: Analysis of the outcomes of the Palliative Care pathway (Application in WA Ethics, already approved by WA Aboriginal Health Ethics)- 2014PI: Survey of Co-morbidity burden in patients on dialysis in Western Australia (2014 – as a part of Dialysis Plan 2015-2025)PI: Survey of Carer needs in in patients on dialysis in Western Australia (2014 – as a part of Dialysis Plan 2015-2025)
CURREnt projects (published projects are excluded) Prospective assessment of QoL, Comorbidity burden and Symptom burden in patients on HD (Project at Armadale Dialysis Unit)  
NURSE PRACTITIONER ROLE RELATED PUBLICATIONS Hepatitis B Vaccination in Late (Stage 4 and 5) Chronic Kidney Disease   http://www.nursing.health.wa.gov.au/docs/career/np/SMAHS/AKDH_HepatitisB_Vaccination.pdf   Approved 16 Feb 2010   Warfarin Therapy in Haemodialysis Patients         http://www.nursing.health.wa.gov.au/docs/career/np/SMAHS/AKDH_Warfarin_Therapy.pdf     Approved 23 April 2010 Management of Renal Anaemia in Stage 4/5 Chronic Kidney Disease (Version 3) http://www.nursing.health.wa.gov.au/docs/career/np/SMAHS/AKDH_Man_renal_anaemia.pdf   Revised 2014, Approved Dec 2014.Management of Hyperphosphatemia in Chronic Kidney Disease http://www.nursing.health.wa.gov.au/docs/career/np/SMAHS/AKDH_Management_Hyperphosphataemia.pdf   Approved 2007.
Industry sponsored clinical research (Principal or Co-Investigator):   FER-CKD (VIFOR) 2010- 2011: An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject® High- and Low-dosage Regimens) versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects with Non-dialysis-dependent Chronic Kidney Disease.
PRIMS trial: A Prospective, Immunogenicity Surveillance (PRIMS) Registry to Determine the Incidence of Erythropoietin Antibody Mediated Pure Red Cell Aplasia (PRCA) Among Patients With Chronic Renal Failure and Subcutaneous Exposure to Recombinant Erythropoietin Products
BALANZ trial: Multi-centre, multi-country randomized controlled trial was to determine whether neutral pH, low GDP dialysate better preserves residual renal function in PD patients over a 2 year period compared with conventional dialysate
RESTORE trial: Removal Of Tacrolimus For Sirolimus Following Thymoglobulin Induction On The Development of Regulatory T Cells (RESTORE)
SPICE trial: 09/275 A study of the pharmacokinetics and safety of deferasirox (Exjade®) in haemodialysis dependent subjects with chronic kidney disease, with secondary iron overload from intravenous iron and erythropoietin therapy: The SPICE study
SHARP Trail: Co-Investigator This randomised double-blind trial included 9270 patients with chronic kidney disease (3023 on dialysis and 6247 not) with no known history of myocardial infarction or coronary revascularisation. Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.
EVOLVE Trial – Co-investigator RCT in dialysis: In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate-to-severe secondary hyperparathyroidism who were undergoing dialysis.
COLLABORATIVE TRIAL GROUP: Co-Investigator The Effect of Sulodexide in Overt Type 2 Diabetic proteinuria – Co-investigator  
(UPDATED MAY 2019) ABSTRACT SUBMISSIONS IN NATIONAL /international confererences  TSANZ 2019: P Howson, H KULKARNI, A Chakera, W Lim. Successful simultaneous liver-kidney transplant with high level DSA using low immunosuppressive regimen.
ANZSN 2017: N. Aung, J Spiro, I. Gilfillan, H KULKARNI. Massive pulmonary embolism and rt atrium thrombus in a cadaveric renal transplant recipient with underlying focal segmental glomerulosclerosis ANZSN 2016: R Holman, S Mukhedkar, R Sinniah H. KULKARNI. Sunitinib induced acute interstitial nephritis-a case report. Nephrology 21, 259-259 Joseph B, Light C, KULKARNI H. Validation of escalation criteria and adult dialysis observation and response chart in dialysis unit.  NEPHROLOGY 21, 182-182 ANZSN 2015: C Light, H KULKARNI. Booster Hepatitis B Vaccination in haemodialysis patients – 5 year prospective study.  NEPHROLOGY 20, 26-26 H KULKARNI, C Light. Cholecalciferol (Vit D) Therapy for low serum Vit D levels (LSVDL) in haemodialysis (HD) over 52 months -A prospective observational study. NEPHROLOGY 20, 67-67.
ANZSN 2014: Light C, KULKARNI H. Safety and Efficacy of 200 mg IV Iron Polymaltose as push bolus in hemodialysis population: A Pilot Study ANZSN 2014 Graves A, Lisweski D, Adris N, Ferrari P, KULKARNI H.  IV Calcium infusions (IV-Ca) following surgical parathyroidectomy (sPTX) in advanced chronic kidney disease (CKD): A centre experience NEPHROLOGY 19, 21-21, 2014. W Hoy, HG Healy, D Waugh, M Jose, H KULKARNI, I Katz,  S Pirabhahar, R Walker, C Nelson, K Panaretto, A Salisbury and T Mathew. Towards a national surveillance network for chronic Kidney disease (CKD).
ANZSN 2014 D Wallooppillai, S Ognenis, P Ferrari, H KULKARNI.  ­Clinico-pathological effects in Renal Transplant recipients with mammalian target of Rapamycin inhibitors – A Centre Audit. ANZSN 2014
ANZSN 2013: Ryan Jo, KULKARNI H, Ferrari P:  Serum Gentamycin levels are not warranted with Gentamicin– Citrate Locks for Hickman Catheters: Audit. ANZSN- Brisbane 2013. Graves A, Texler M, Manning L, KULKARNI H:  Malakoplakia in a renal transplant recipient: Successful management outcome: Case report. ANZSN- Brisbane 2013. Light C, Phikoo A, KULKARNI H. Aggressive Phosphate Lowering Project (OPAL) at Satellite Dialysis Unit (MDT team involvement). ANZSN- Brisbane 2013. Graves A, KULKARNI H. mTORi associated cerebral venous sinus thrombosis: A Case Report. ANZSN- Brisbane 2013. ANZSN 2011:  Light C, Kulkarni H. Cholecalciferol thearpy in 25OH Vit D Haemodialysis population: A Pilot Study. ANZSN 2011. Chong S, Kulkarni H.  Membranous GN with distal renal tubular acidosis- a  Case Report. ANZSN 2011.
ANZSN 2010: Kulkarni H, Ferrari P, Betti S, Olynyk J: Serum Iron markers do not predict changes in Liver Iron Content upon High dose parenteral iron in predialysis CKD patients:
ANZSN 2010
ANZSN/ ASN 2009: Kulkarni H, Ferrari P, Olynyk J: Hyperferritinemia correlated to iron overload in haemodialysis population: ANZSN 2009.      George Chin, R Holman, H Kulkarni. “Sweets Syndrome in a renal transplant recipient taking Azathioprine and Leflunomide: A case report”. Am Soc Neph, Annual Confer, 2009.
 ANZSN 2008: Kulkarni H, Olynyk J, Harrison C, Ferrari P. Magnetic Resonance Imaging demonstrates iron overload in patients on long term haemodialysis. Oral and Poster Presentation: ANZSN, 2008 Wright S, Kulkarni H, Yeap B, Ferrari P. Thyroid function after radioiodinated contrast in haemodialysis population. Poster Presentation for ANZSN 2008.
ANZSN 2007: Abraham A, Singer R, Kulkarni H. Relapse of Nephrotic Range Proteinuria following conversion to mTOR therapy with Recurrence of Membranous GN in allograft: Am Soc of Nephrology Annual Meeting, San Francisco 2007:
ANZSN 2006: Kulkarni H, Ferrari P. 1 year data on intradermal Hepatitis B vaccination protocol on patients with Stage 4 and 5 Chronic Kidney Disease. ANZSN Annual Conference: Melbourne. Sept 2006.
ANZSN 2005: Kulkarni H, Warr K. Traumatic “Snapping” of Hickman catheters: 4 Case Reviews. ANZSN Annual Conference: Sydney. Sept 2005
ANZSN 2004: Kulkarni H et al: Case report: Hypoglycemia during IV and oral Ganciclovir treatment in a renal transplant recipient. ANZSN Annual Conference: Adelaide Sept 2004
WCN 2003: Kulkarni H, Henning P, Jureidini K. Cystatin C in term and Preterm infants over first 3 months of age.  World Congress of Nephrology, Berlin (2003)
ANZSN 2002: Kulkarni H, Hennig P, Vigneswaran R, Jureidini F.  Cystatin C in term and Preterm infants over first 3 months of age. ANZSN, SEPT 2002.
1999: Kulkarni H, Bethelham K,  Martin A, Goldwater P. O group E. coli serology and its clinical correlation in the patients with HUS epidemic in S. Australia in 1995. Second European Congress on Enterhemorrhagic E. coli, Brussels, Acta Clinica Belgica; 54-1, p 37; 1999.
1998: Kulkarni H, Jureidini F. Improvement with Kindergen PROD in Chronic renal failure in Children. 9th International Congress on Nutrition and Renal Disease
1997: Kulkarni H, Kirpalani A (et al):  Ann Cong, Int Society of Nephrology, SYDNEY,. * Neoral as an acceptable alternative for Sandimmune. * Post renal transplant acidosis.                            * Hepatitis B & C in the renal transplantation. Kirpalani AL, Ameen A,, KULKARNI H, Oza UG, Phadke AG. Hyperlactatemia in recipients immediately following renal transplant surgery. Proceedings of 9th Annual Conference of Ind Soc of Organ Transplantation (Jan 1997): Page 85. Bichu SD, Kirpalani AL, Iyer VK, KULKARNI H, Oza UG. Is Hepatitis c INFECTION worse than Hepatitis B in renal transplant recipients? Proceedings of 9th Annual Conference of Ind Soc of Organ Transplantation (Jan 1997): Page 96.
1996:  KULKARNI H, Kirpalani A. Comparison of polysulphone and cuprophane dialysers in CAVHD’s. At Bombay Hospital Research Society Meeting, June 1996. Nocardiosis in the renal transplant recipients – A center experience. At Bombay Nephrology Meet, July 1996.